| 开盘价:-- | 最高价:-- | 最低价:-- | 52周最高价:-- | 52周最低价:-- |
| 成交量:-- | 平均成交量:-- | 市值:-- | 市盈率:-- | 预期市盈率:-- |
| 每股收益:-- | 贝塔系数:-- | 股息:-- | 收益率:-- | 总股本:-- |
| 证券代码:tril | 公司名称:Trillium Therapeutics ULC | 公司中文简称: |
| 公司简介： Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. |
||
| 公司网站： http://www.trilliumtherapeutics.com |
||
| 公司地址： 1055 West Georgia Street Vancouver |
||